Document:

Form of Warrant issued to agents on June 1 and June 29, 2007

 EXHIBIT 4.3 
 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE            , 2007.

 WITHOUT PRIOR WRITTEN APPROVAL OF THE TSX VENTURE EXCHANGE (“TSXV”) AND COMPLIANCE WITH ALL APPLICABLE SECURITIES
LEGISLATION, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE TRADED ON OR THROUGH THE FACILITIES OF THE TSXV OR OTHERWISE IN CANADA OR TO OR FOR THE BENEFIT OF A CANADIAN RESIDENT UNTIL
            , 2007. 
 AGENT’S COMPENSATION OPTION
AGREEMENT 
 AGREEMENT is made as of            ,
2007. 
 BETWEEN: 
 MED BIOGENE INC.  
 (hereinafter referred to as the “Company”) 
 OF THE FIRST PART 
 – and – 
 (hereinafter referred to as the “Agent”) 
 OF THE SECOND PART 
 WHEREAS the Company has agreed to grant to the Agent, as partial compensation payable to the Agent for services rendered in connection with the private placement (the “Offering”) of certain units (the
“Units”) of the Company on            , 2007, a non-assignable option (the “Compensation Option”) to purchase     units (the
“Optioned Units”) at a price of $0.45 per Optioned Unit. Each Optioned Unit is comprised of one common share in the capital of the Company (an “Optioned Share”) and one common share purchase warrant (an
“Optioned Warrant”). Each Optioned Warrant entitles the holder thereof to acquire one common share in the capital of the Company (an “Underlying Share”) at an exercise price of $0.65 for a period of 36 months
from the closing date of the Offering; provided that if, at any time following expiry of the applicable hold period, the closing price of the common shares in the capital of the Company on the TSX Venture Exchange, or such major stock exchange or
quotation system as the common shares are then trading or are listed, is greater than $0.85 for 20 or more consecutive trading days, the Company may give notice to the holders of Optioned Warrants that the expiry date for exercise of the Optioned
Warrants has been accelerated and that the Optioned Warrants will expire on the 20th business day following the date of such notice. 
 NOW THEREFORE in consideration of the mutual covenants herein contained, the sufficiency and receipt of which are hereby acknowledged, the parties hereto agree as follows: 
 1. Option to Purchase. 
 As
partial consideration for the Agent’s services performed by it and for services rendered in connection with the Offering, the Company hereby grants to the Agent, without payment of any further consideration, the Compensation Option. The
Compensation Option shall be exercisable in whole or in part at any time and from time to time during the Term to acquire Optioned Units. 

 The terms and conditions of the Optioned Warrants shall be identical to the terms and
conditions of the common share purchase warrants (the “Warrants”) to be issued pursuant to the Offering to purchasers of the Units upon the exercise thereof. 
 2. Term of Option. 
 Notwithstanding any other provision of this Agreement,
the Compensation Option shall be exercisable in whole or in part at any time prior to 4:00 p.m. (Vancouver time) on the day which is 18 months from the closing date of the Offering (the “Term”). 
 3. Manner of Exercise of Option. 
 Subject to paragraph 4, the Agent may exercise this Compensation Option to purchase on a cumulative basis, to the extent hereinafter provided, all or any part of the Optioned Units, and such right shall be continuing and cumulative
during the Term until all of the Optioned Units have been purchased. 
 4. Notice of Exercise of Option and Payment. 
 This Compensation Option shall be exercised in whole or in part upon providing notice in writing to the Company at Med BioGene Inc., #300
- 2386 East Mall, Gerald McGavin Building, Vancouver, British Columbia V6T 1Z3, (fax: (604) 827-5120), or at such other place as the Company’s executive office may then be located (a “Notice”), together with a
certified cheque or bank draft representing the subscription price for the number of Optioned Units purchased. 
 5. Right of a Shareholder.

 Within five (5) business days after receipt of the Notice and payment in full of the subscription price for the total
number of Optioned Units to be purchased, the Company shall cause the Agent to be recorded in its register of shareholders as holder of the number of fully paid, non-assessable Optioned Shares so purchased (the date upon which the Agent is so
recorded as registered holder being referred to in this paragraph 5 as the “Registry Date”). In the case of the Optioned Warrants, within five (5) business days after receipt of the Notice, the Company shall cause to be
delivered to the Agent a warrant certificate (in the form appended hereto as Schedule “A”) for the number of Optioned Warrants to which the Agent is entitled by virtue of the Notice. The Agent shall have full rights as a shareholder with
respect to Optioned Shares acquired pursuant to this Compensation Option on or after the Registry Date, and no adjustment shall be made for dividends or other rights for which the record date is prior to the Registry Date. The Company agrees to
issue share certificates in respect of all Optioned Shares so purchased as soon as practicable after the Registry Date, and in any event within five (5) business days thereafter. Under no circumstances shall the Company be obliged to issue any
fractional Optioned Shares or fractional Optioned Warrants upon the exercise of the Compensation Option. The Company shall not pay any amounts to the Agent in satisfaction of the right to otherwise have received a fraction of an Optioned Share or a
fraction of an Optioned Warrant. 
 6. No Transfer of Option. 
 Neither the Compensation Option nor the Compensation Warrant may be assigned or transferred. 
  

 – 2 – 

 7. Adjustments. 
 In the event, at any time or from time to time, of a subdivision, consolidation or reclassification of the share capital of the Company, the payment of stock dividends by the Company or other relevant
changes in the capital of the Company prior to the exercise by the holder, in full, of the Optioned Units, the Optioned Warrants and Optioned Shares shall be proportionately adjusted so that the holder of the Optioned Unit shall from time to time,
upon the exercise of the option to purchase the Optioned Units, be entitled to receive the number of Optioned Shares and Underlying Shares it would have held following such change in the capital of the Company if the holder had exercised the
Optioned Unit immediately prior to such change in the capital of the Company and held to the Optioned Shares and the Underlying Shares obtained from the exercise thereof immediately prior to such change in the capital of the Company. 
 8. Covenants of the Company. 
 The Company hereby represents and covenants that: 
  

	 	(a)	all Optioned Shares, Underlying Shares and Optioned Warrants that may be issued upon the exercise of this Compensation Option shall, upon issuance, be validly issued
and, in the case of the Optioned Shares and Underlying Shares, fully paid and non-assessable shares; and 

  

	 	(b)	at all times during the Term, the Company shall have authorised and reserved for issuance a sufficient number of common shares to provide for the exercise of the
Agent’s rights hereunder. 

 9. Regulatory Approval. 
 This Agreement and the obligations of the Company to sell and deliver Optioned Shares shall be subject to the receipt of any required prior
approval of any governmental or other regulatory authority or stock exchange having jurisdiction over the securities of the Company. 
 10.
Time of the Essence. 
 Time shall be of the essence of this Agreement. 
 11. Governing Law. 
 This
Agreement and the Compensation Option granted hereunder shall be governed by and be interpreted in accordance with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. The parties hereto irrevocably attorn
to the jurisdiction of the courts of the Province of British Columbia. 
 [The remainder of this page is intentionally blank.]

  

 – 3 – 

 IN WITNESS WHEREOF the parties hereto duly executed this agreement as of the date first above
written. 
  

			
	MED BIOGENE INC.
		
	Per:	 	  

		 	Erinn Broshko
		 	Authorized Signing Officer
		
	Per:	 	  

		 	Authorized Signing OfficerForm of Warrant issued to investors on August 7 and September 18, 2008

 EXHIBIT 4.4 
 THE WARRANTS REPRESENTED HEREBY WILL BE VOID AND OF NO VALUE UNLESS EXERCISED WITHIN THE TIME LIMITS HEREIN PROVIDED. 
 MED BIOGENE INC. 
 COMMON SHARE PURCHASE WARRANT 

DATED:             , 2008 
  

			
	Number of Warrants:	  	Warrant Certificate No.:     

 THIS IS TO CERTIFY THAT, for value received, 
 (the “Holder”) is the registered holder of      share purchase warrants (the “Warrants”) of
MED BIOGENE INC. (the “Company”). Each Warrant entitles the Holder to subscribe for and purchase, subject to the terms hereof including, without limitation, certain adjustment provisions, one common share (a
“Share”) in the share capital of the Company for an exercise price of $0.20 per Share (the “Exercise Price”) until 4:00 p.m. (Vancouver time) on
            , 2010 (the “Expiry Time”) after which time the Warrants represented hereby shall expire; provided that, if, over a period of 20 consecutive trading days after
             , 2008 (the “Closing Date”) and until the Expiry Time, the daily volume weighted average trading price of the Company’s common shares on the TSX Venture
Exchange (the “TSXV”), or such other stock exchange where the majority of the trading volume occurs, exceeds $0.40 on each of those 20 consecutive days, the Company may give notice in writing to the Warrant Holder within 30 days of
such an occurrence that the Warrants shall expire at 4:00 p.m. (Vancouver time) on the 30th day following the giving of such notice unless exercised by the Holder prior to such date. 
 The right to acquire Shares may only be exercised by the Holder within the time set forth above by: 
  

	 	(a)	duly completing and executing the Exercise Form attached hereto as Appendix A; and 

  

	 	(b)	surrendering this Warrant Certificate and delivering a completed Exercise Form and a certified cheque or bank draft in an amount equal to the Exercise Price multiplied
by the number of Shares to be acquired, subject to adjustment in accordance with the terms hereof, to the Company at its principal office address shown on the Exercise Form. 

 This Warrant Certificate shall effectively be surrendered only upon personal delivery hereof or, if sent by mail or other means of
transmission, upon actual receipt thereof by the Company at the address shown on the Exercise Form or such other address as may be specified by the Company, in a written notice to the Holder, from time to time. 

 Upon the exercise of all or any of the Warrants in the manner described above, the person or
persons in whose name or names the Shares issuable upon exercise of the Warrants are to be issued shall be deemed for all purposes to be the holder or holders of record of such Shares and the Company covenants that it will, within three business
days of the surrender of this Warrant Certificate, cause to be sent to the person or persons at the address or addresses specified in the Exercise Form certificates representing such Shares . 
 The Holder of this Warrant Certificate may acquire any lesser number of Shares than the total number of Shares which may be acquired upon
exercise of the Warrants represented by this Warrant Certificate. In such event, the Holder shall be entitled to receive a new Warrant Certificate representing Warrants exercisable to acquire up to the balance of the Shares which may be acquired.

 Subject to the terms hereof and the terms set forth in the Transfer Form attached hereto, the Warrants may be transferred. No
transfer of the Warrants will be effective unless this Warrant Certificate, accompanied by a duly executed Transfer Form or other instrument of transfer in such form as the Company may from time to time prescribe, together with such evidence of the
genuineness of each endorsement, execution and authorization and of other matters as may reasonably be required by the Company, are delivered to the Company. No transfer of the Warrants will be made if in the opinion of counsel to the Company such
transfer would result in the violation of any applicable securities laws. 
 The Holder of this Warrant Certificate may, at any
time prior to the Expiry Time, upon surrender of this Warrant Certificate to the Company, exchange this Warrant Certificate for other Warrant Certificates entitling the Holder to acquire, in the aggregate, the same number of Shares as may be
acquired under this Warrant Certificate. 
 The holding of the Warrants evidenced by this Warrant Certificate shall not
constitute the Holder hereof a shareholder of the Company or entitle the Holder to any right or interest in respect thereof except as expressly provided for herein. 
 From and after the date hereof, the Exercise Price and the number of Shares deliverable upon the exercise of the Warrants will be subject to adjustment as follows: 
  

	 	(a)	 In case of any reclassification of the Shares or change of the Shares into other shares, or in case of the consolidation, merger, reorganization or
amalgamation of the Company with or into any other Company or entity which results in any reclassification of the Shares or a change of the Shares into other shares, or in case of any transfer of the undertaking or assets of the Company as an
entirety or substantially as an entirety to another person (any such event, a “Reclassification of Shares”), at any time prior to the Expiry Time, the Holder shall, after the effective date of such Reclassification of Shares and
upon exercise of the right to purchase Shares hereunder, be entitled to receive, and shall accept, in lieu of the number of Shares to which the Holder was theretofore entitled upon such exercise, the kind and amount of shares and other securities or
property which the Holder would have been entitled to receive as a result of such Reclassification of Shares if, on the effective date thereof, the Holder had been the registered holder of the number of Shares to which the Holder was theretofore
entitled upon such exercise. If necessary,

  

 - 2 - 

	 	 
appropriate adjustments shall be made in the application of the provisions set forth in this section with respect to the rights and interests thereafter of the Holder in order that the provisions
set forth in this section shall thereafter correspondingly be made applicable as nearly as may be reasonable in relation to any shares or other securities or property thereafter deliverable upon the exercise of the Warrants evidenced hereby.

  

	 	(b)	If and whenever at any time prior to the Expiry Time the Company shall: 

  

	 	(i)	subdivide the Shares into a greater number of shares; 

  

	 	(ii)	consolidate the Shares into a lesser number of shares; or 

  

	 	(iii)	issue Shares, Participating Shares or Convertible Securities (both such terms as defined below in paragraph (g)) to all or substantially all of the holders of Shares by
way of a stock dividend or other distribution on the Shares payable in Shares, Participating Shares or Convertible Securities; 

 (any such event, a “Capital Reorganization”) and any such event results in an adjustment in the Exercise Price pursuant to paragraph (c), the number of Shares purchasable pursuant to the
Warrants evidenced hereby shall be adjusted contemporaneously with the adjustment of the Exercise Price by multiplying the number of Shares theretofore purchasable on the exercise thereof by a fraction the numerator of which shall be the Exercise
Price in effect immediately prior to such adjustment and the denominator of which shall be the Exercise Price resulting from such adjustment. 
  

	 	(c)	If and whenever at any time prior to the Expiry Time, the Company shall undertake a Capital Reorganization, the Exercise Price shall, on the effective date, in the case
of a subdivision or consolidation, or on the record date, in the case of a stock dividend, be adjusted by multiplying the Exercise Price in effect on such effective date or record date by a fraction: (A) the numerator of which shall be the
number of Shares and Participating Shares outstanding immediately before giving effect to such Capital Reorganization; and (B) the denominator of which is the number of Shares and Participating Shares outstanding immediately after giving effect
to such Capital Reorganization. The number of Shares and Participating Shares outstanding shall include the deemed conversion into or exchange for Shares or Participating Shares of any Convertible Securities distributed by way of stock dividend or
other such distribution. Such adjustment shall be made successively whenever any event referred to in this paragraph shall occur. 

  

	 	(d)	Any issue of Shares, Participating Shares or Convertible Securities by way of a stock dividend or other such distribution shall be deemed to have been made on the
record date thereof for the purpose of calculating the number of outstanding Shares under paragraphs (e) and (f). 

  

 - 3 - 

	 	(e)	If and whenever at any time prior to the Expiry Time, the Company shall fix a record date for the issuance of rights, options or warrants (other than the Warrants
evidenced hereby) to all or substantially all the holders of Shares entitling them, for a period expiring not more than 45 days after such record date, to subscribe for or purchase Shares, Participating Shares or Convertible Securities at a price
per share (or having a conversion or exchange price per share) of less than 95% of the Current Value (as defined below) of the Shares on such record date (any such event, a “Rights Offering”), the Exercise Price shall be adjusted
immediately after such record date so that it shall equal the price determined by multiplying the Exercise Price in effect on such record date by a fraction: 

  

	 	(i)	the numerator of which shall be the aggregate of: (A) the number of Shares outstanding on such record date; and (B) a number determined by dividing whichever
of the following is applicable by the Current Value (as hereinafter defined) of the Shares on the record date: (1) the amount obtained by multiplying the number of Shares or Participating Shares which the holders of Shares are entitled to
subscribe for or purchase by the subscription or purchase price; or (2) the amount obtained by multiplying the maximum number of Shares or Participating Shares which the holders of Shares are entitled to receive on the conversion or exchange of
the Convertible Securities by the conversion or exchange price per share; and 

  

	 	(ii)	the denominator of which shall be the aggregate of: (A) the number of Shares outstanding on such record date; and (B) whichever of the following is
applicable: (1) the number of Shares or Participating Shares which the holders of Shares are entitled to subscribe for or purchase; or (2) the maximum number of Shares or Participating Shares which the holders of Shares are entitled to
receive on the conversion or exchange of the Convertible Securities. 

 Any Shares owned by or held for the account
of the Company shall be deemed not to be outstanding for the purpose of any such computation. Such adjustment shall be made successively whenever such a record date is fixed. 
 To the extent that such Rights Offering is not so made or any such rights, options or warrants are not exercised prior to the expiration
thereof, the Exercise Price shall then be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or if such expired rights, options or warrants had not been issued. 
  

	 	(f)	If and whenever at any time prior to the Expiry Time, the Company shall fix a record date for the distribution to all or substantially all the holders of Shares of:

  

	 	(i)	shares of any class, whether of the Company or any other company; 

  

	 	(ii)	rights, options or warrants; 

  

	 	(iii)	evidences of indebtedness; or 

  

	 	(iv)	other assets or property; 

  

 - 4 - 

 and if such distribution does not constitute a Capital Reorganization or a Rights Offering
or does not consist of rights, options or warrants entitling the holders of Shares to subscribe for or purchase Shares, Participating Shares or Convertible Securities for a period expiring not more than 45 days after such record date and at a price
per share (or having a conversion or exchange price per share) of at least 95% of the Current Value of the Shares on such record date (any such non-excluded event, a “Special Distribution”), the Exercise Price shall be adjusted
immediately after such record date so that it shall equal the price determined by multiplying the Exercise Price in effect on such record date by a fraction: (A) the numerator of which shall be the amount by which (1) the amount obtained
by multiplying the number of Shares outstanding on such record date by the Current Value of the Shares on such record date, exceeds (2) the aggregate fair market value (as determined by the external auditors of the Company, which determination
shall be conclusive) to the holders of such Shares of such Special Distribution; and (B) the denominator of which shall be the total number of Shares outstanding on such record date multiplied by such Current Value. 
 Any Shares owned by or held for the account of the Company shall be deemed not to be outstanding for the purpose of any such computation.
Such adjustment shall be made successively whenever such a record date is fixed. 
 To the extent that such Special Distribution
is not so made or any such rights, options or warrants are not exercised prior to the expiration thereof, the Exercise Price shall then be readjusted to the Exercise Price which would then be in effect if such record date had not been fixed or if
such expired rights, options or warrants had not been issued. 
  

	 	(g)	For the purpose of this Warrant: (i) “Participating Share” means a share (other than a Share) that carries the right to participate in earnings to
an unlimited degree; and (ii) “Convertible Security” means a security convertible into or exchangeable for a Share or a Participating Share or both. 

  

	 	(h)	Notwithstanding the foregoing, no adjustment shall be made pursuant to this Warrant Certificate in respect, from time to time, of: 

  

	 	(i)	the issue by the Company of Shares purchasable on exercise of the Warrants represented by this Warrant Certificate; 

  

	 	(ii)	dividends (payable in cash, Shares or Participating Shares) declared payable on the Shares in any fiscal year of the Company to the extent that the aggregate value of
such dividends, when aggregated with the aggregate value of any dividends previously declared payable on the Shares in such fiscal year, do not exceed 50% of the aggregate consolidated net income of the Company, before extraordinary items, for its
immediately preceding fiscal year; or 

  

 - 5 - 

	 	(iii)	the issue by the Company of Shares pursuant to any stock option, stock option plan, stock purchase plan or benefit plan in force at the date hereof for directors,
officers, employees, advisers or consultants of the Company, as such option or plan is amended or superseded from time to time in accordance with the requirements of the of the TSXV or any other stock exchange or quotation system on which the Shares
are then listed or quoted for trading and applicable securities laws, and such other stock option, stock option plan, stock purchase plan or benefit plan as may be adopted by the Company in accordance with the requirements of the of the TSXV or any
other stock exchange or quotation system on which the Shares are then listed or quoted for trading and applicable securities laws. 

  

	 	(i)	In any case in which this Warrant Certificate shall require that an adjustment shall become effective immediately after a record date for an event referred to herein,
the Company may defer, until the occurrence of such event, issuing to the Holder, upon the exercise of the Warrants evidenced hereby after such record date and before the occurrence of such event, the additional Shares or securities or other
property issuable upon such exercise by reason of the adjustment required by such event; provided, however, that the Company shall deliver to the Holder an appropriate instrument evidencing the Holder’s right to receive such additional Shares
or securities or other property upon the occurrence of the event requiring such adjustment and the right to receive any distributions made on any such additional Shares or securities or other property on and after such exercise.

  

	 	(j)	The adjustments provided for in this Warrant Certificate are cumulative, shall, in the case of adjustments to the Exercise Price, be computed to the nearest one-tenth
of one cent and shall apply (without duplication) to successive Reclassifications of Shares, Capital Reorganizations, Rights Offerings and Special Distributions; provided that, notwithstanding any other provision of this section, no adjustment of
the Exercise Price shall be required unless such adjustment would require an increase or decrease of at least 1% of the Exercise Price then in effect (except upon a consolidation of the outstanding Shares); provided, however, that any adjustments
which by reason of this paragraph are not required to be made shall be carried forward and taken into account in any subsequent adjustment. 

  

	 	(k)	No adjustment in the number of Shares which may be purchased upon exercise of the Warrants evidenced hereby or in the Exercise Price shall be made pursuant to this
Warrant Certificate if the Holder is entitled to participate in such event on the same terms mutatis mutandis as if the Holder had exercised the Warrants evidenced hereby for Shares prior to the effective date or record date of such event.

  

	 	(l)	In the event of any question arising with respect to the adjustments provided in this Warrant Certificate, such question shall conclusively be determined by a firm of
chartered accountants appointed by the Company (who may be the Company’s auditors) and acceptable to the Holder, acting reasonably. Such accountants shall have access to all necessary records of the Company and such determination shall be
binding upon the Company and the Holder. 

  

 - 6 - 

	 	(m)	As a condition precedent to the taking of any action which would require an adjustment in the subscription rights pursuant to the Warrant, including the Exercise Price
and the number of such classes of shares or other securities or property which are to be received upon the exercise thereof, the Company shall take all corporate action which may, in the opinion of external counsel, be necessary in order that the
Company has reserved and there will remain unissued out of its authorized capital a sufficient number of Shares for issuance upon the exercise of the Warrants evidenced hereby, and that the Company may validly and legally issue as fully paid and
non-assessable all the shares of such classes or other securities or may validly and legally distribute the property which the Holder is entitled to receive on the full exercise thereof in accordance with the provisions hereof.

  

	 	(n)	At least 14 days prior to the effective date or record date, as the case may be, of any event which requires an adjustment in the subscription rights pursuant to this
Warrant Certificate, including the Exercise Price and the number and classes of shares or other securities or property which are to be received upon the exercise thereof, the Company shall give notice to the Holder of the particulars of such event
and the required adjustment. 

  

	 	(o)	The Company shall not be required to issue fractional Shares in satisfaction of its obligations hereunder. If any fractional interest in a Share would, except for the
provisions of this section, be deliverable upon the exercise of a Warrant, the Company shall in lieu of delivering the fractional Shares therefor satisfy the right to receive such fractional interest by payment to the holder of such Warrant of an
amount in cash equal (computed in the case of a fraction of a cent to the next lower cent) to the value of the right to acquire such fractional interest on the basis of the Current Value at the date of exercise of the Warrant.

  

	 	(p)	If this Warrant Certificate becomes stolen, lost, mutilated or destroyed, the Company shall, on such terms as it may in its discretion acting reasonably impose, issue
and deliver to the Holder a new Warrant Certificate of like denomination, tenor and date as the Warrant Certificate so stolen, lost, mutilated or destroyed. 

 For the purpose of any computation under this Warrant Certificate, the “Current Value” of the Shares at any date shall be determined as: 
  

	 	(a)	the weighted average closing price of the Shares traded through the facilities of the TSXV for the five trading days prior to that date; 

  

	 	(b)	if the Shares are not listed on the TSXV, the weighted average closing price of the Shares traded through the facilities of such other stock exchange or quotation
system on which the Shares are listed or through which the Shares are quoted for the five trading days prior to that date; or 

  

	 	(c)	if the Shares are not listed on the TSXV or any other stock exchange or quoted through a quotation system, the fair value thereof as determined in good faith by an
independent brokerage or accounting firm selected by the Company and satisfactory to the Holder, acting reasonably. The Company shall be solely responsible for paying all fees and expenses of such independent brokerage firm.

  

 - 7 - 

 This Warrant Certificate shall be governed and construed in accordance with the laws of the
Province of British Columbia and the federal laws of Canada applicable therein. The parties hereto irrevocably attorn to the jurisdiction of the courts of the Province of British Columbia. 
 Time shall be of the essence hereof. 
 IN WITNESS WHEREOF the Company has caused this Warrant Certificate to be executed by its duly authorized officer. 
  

			
	MED BIOGENE INC.
		
	 Per:
	 	  

		 	Authorized Signatory

  

 - 8 - 

 APPENDIX A 
 EXERCISE FORM 
  

			
	TO:	  	MED BIOGENE INC.
		  	#300 - 2386 East Mall
		  	Gerald McGavin Building
		  	Vancouver, British Columbia V6T 1Z3

 The undersigned holder of the attached Warrant Certificate hereby subscribes for
     common shares (the “Shares”) in the share capital of MED BIOGENE INC. pursuant to the terms of the Warrant Certificate at the Exercise Price (as defined in the Warrant Certificate) on the terms
specified in the Warrant Certificate and contemporaneously with the execution and delivery hereof makes payment therefor on the terms specified in the Warrant Certificate. 
 The undersigned irrevocably hereby directs that      Shares be issued and delivered as follows:

  

					
	 Name in Full
	  	 Address
	  	 Number of Shares

	  
	  	  
	  	  

	  
	  	  
	  	  

 DATED      this day of
        ,         . 
  

			
	WARRANTHOLDER:
		
	 Per:
	 	  

		 	Authorized Signatory

 Instructions: 
 The registered holder may exercise its right to receive Shares by completing this form and surrendering this form, the Warrant Certificate representing the Warrants being exercised and payment of the
Exercise Price as specified above to the Company at its principal office address as set out above. Certificates for Shares will be sent to the holder within three business days after the exercise of the Warrants. 

 APPENDIX B 
 TRANSFER FORM 
 For value received, the undersigned
hereby sells, transfers and assigns unto
                                         
                                         
                                         
                                         
                                         
    
                             (please print name of transferee) 
  

					
	of	  	  
	 	
		  	  
	 	
		  	  
	 	
		  	(please print address of transferee)	 	

                                        
                                         
                                     warrants represented (please
insert number of warrants to be transferred) 
 by the within certificate. 
 DATED this      day of         , 20        . 
  

	
	  
 NOTICE: THE SIGNATURE TO THIS
TRANSFER MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE WARRANT CERTIFICATE, IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT, OR ANY CHANGE WHATEVER

  

			
	 Signature
	 	
	 guaranteed by:
	 	  

		 	NOTICE: THE SIGNATURE OF THE TRANSFEROR SHOULD BE GUARANTEED BY A BANK, FINANCIAL INSTITUTION OR STOCK BROKER WHOSE SIGNATURE IS ACCEPTABLE TO THE COMPANY.

 The signature of this transfer must correspond exactly with the name as written on
the face page hereof. 
 Warrants shall only be transferable in accordance with applicable laws and the resale of warrants and shares issuable
upon exercise of warrants may be subject to restrictions under such laws.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]